NewBiotics Names President
Pharmaceutical developer NewBiotics Inc. of San Diego, Calif., has named H. Michael Shepard, PhD, as company president.
Shepard was chief scientific officer and vice president of research at Canji, Inc. before taking the position. He helped develop the p53 gene product for cancer therapy and worked with management to secure financing for the company.
NewBiotics is privately held and is primarily researching breakthrough drugs to treat cancer and infectious disease.
Shepard was a Damon Runyon Fellow at Indiana University and received his doctorate in molecular, cellular, and developmental biology.
Point-of-Care Engagement in Long-Term Care Decreasing Infections
November 26th 2024Get Well’s digital patient engagement platform decreases hospital-acquired infection rates by 31%, improves patient education, and fosters involvement in personalized care plans through real-time interaction tools.
Comprehensive Strategies in Wound Care: Insights From Madhavi Ponnapalli, MD
November 22nd 2024Madhavi Ponnapalli, MD, discusses effective wound care strategies, including debridement techniques, offloading modalities, appropriate dressing selection, compression therapy, and nutritional needs for optimal healing outcomes.
The Leapfrog Group and the Positive Effect on Hospital Hand Hygiene
November 21st 2024The Leapfrog Group enhances hospital safety by publicizing hand hygiene performance, improving patient safety outcomes, and significantly reducing health care-associated infections through transparent standards and monitoring initiatives.
